Jiang Y - Search Results

1

Sequestration of NF-kappaB signaling complexes in lipid rafts contributes to repression of NF-kappaB in T lymphocytes under hyperthermia stress.

Yan G, Huang J, Jarbadan NR, Jiang Y, Cheng H. Yan G, et al. Among authors: jiang y. J Biol Chem. 2008 May 2;283(18):12489-500. doi: 10.1074/jbc.M707988200. Epub 2008 Mar 3. J Biol Chem. 2008. PMID: 18316375 Free article.

2

Evidence of LAT as a dual substrate for Lck and Syk in T lymphocytes.

Jiang Y, Cheng H. Jiang Y, et al. Leuk Res. 2007 Apr;31(4):541-5. doi: 10.1016/j.leukres.2006.07.010. Epub 2006 Aug 30. Leuk Res. 2007. PMID: 16938345

3

HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB.

Huang J, Ren T, Guan H, Jiang Y, Cheng H. Huang J, et al. Among authors: jiang y. J Biol Chem. 2009 Mar 6;284(10):6208-17. doi: 10.1074/jbc.M806390200. Epub 2009 Jan 7. J Biol Chem. 2009. PMID: 19129196 Free article.

4

Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.

Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Jiang Y, et al. Cancer. 2009 Aug 15;115(16):3609-17. doi: 10.1002/cncr.24434. Cancer. 2009. PMID: 19526592 Free article. Review.

5

Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?

Jiang Y, Mackley H, Cheng H, Ajani JA. Jiang Y, et al. J Natl Compr Canc Netw. 2010 Jan;8(1):135-44. doi: 10.6004/jnccn.2010.0009. J Natl Compr Canc Netw. 2010. PMID: 20064295 Review.

6

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.

Jiang Y, Mackley H, Cheng H, Ajani JA. Jiang Y, et al. Biomark Med. 2010 Aug;4(4):535-41. doi: 10.2217/bmm.10.74. Biomark Med. 2010. PMID: 20701442 Review.

7

Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.

Wu L, Zhang H, Jiang Y, Gallo RC, Cheng H. Wu L, et al. Among authors: jiang y. Proc Natl Acad Sci U S A. 2018 May 8;115(19):E4453-E4462. doi: 10.1073/pnas.1800550115. Epub 2018 Apr 19. Proc Natl Acad Sci U S A. 2018. PMID: 29674449 Free PMC article.

8

New pharmacological developments in the treatment of hepatocellular cancer.

Gusani NJ, Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H, Ajani JA. Gusani NJ, et al. Among authors: jiang y. Drugs. 2009;69(18):2533-40. doi: 10.2165/11530870-000000000-00000. Drugs. 2009. PMID: 19943706 Clinical Trial.

9

Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.

Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Jiang Y, et al. Cancer Biol Ther. 2011 Oct 1;12(7):574-85. doi: 10.4161/cbt.12.7.15971. Epub 2011 Oct 1. Cancer Biol Ther. 2011. PMID: 21795855 Free PMC article.

10

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.

You H, Ding W, Dang H, Jiang Y, Rountree CB. You H, et al. Among authors: jiang y. Hepatology. 2011 Sep 2;54(3):879-89. doi: 10.1002/hep.24450. Epub 2011 Jul 19. Hepatology. 2011. PMID: 21618573 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44,674 results

Search Page

Filters